These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22170277)

  • 1. Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy.
    Fasano A; Di Matteo A; Vitale C; Squintani G; Ferigo L; Bombieri F; Santangelo G; Amboni M; Barone P; Tinazzi M
    Mov Disord; 2011 Dec; 26(14):2578-80. PubMed ID: 22170277
    [No Abstract]   [Full Text] [Related]  

  • 2. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases.
    Vitale C; Santangelo G; Erro R; Errico D; Manganelli F; Improta I; Moccia M; Barone P
    Parkinsonism Relat Disord; 2013 Apr; 19(4):483-4. PubMed ID: 23305965
    [No Abstract]   [Full Text] [Related]  

  • 3. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pisa syndrome after rasagiline therapy in a patient with Parkinson's disease.
    Valentino F; Cosentino G; Fierro B; Realmuto S; Mastrilli S; Savettieri G; D'Amelio M
    Neurol Sci; 2015 Dec; 36(12):2305. PubMed ID: 26335016
    [No Abstract]   [Full Text] [Related]  

  • 5. Rasagiline and Pisa syndrome in Parkinson's disease patients.
    Solla P; Cannas A; Orofino G; Marrosu F
    Neurol Sci; 2015 Mar; 36(3):485-6. PubMed ID: 25481627
    [No Abstract]   [Full Text] [Related]  

  • 6. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract]   [Full Text] [Related]  

  • 7. [Rasagiline in Parkinson's disease].
    Linazasoro G
    Neurologia; 2008 May; 23(4):238-45. PubMed ID: 18307054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insidious onset of Pisa syndrome after rasagiline therapy in a patient with Parkinson's disease.
    Valentino F; Cosentino G; Fierro B; Realmuto S; Mastrilli S; Savettieri G; D'Amelio M
    Neurol Sci; 2014 Oct; 35(10):1615-7. PubMed ID: 24770981
    [No Abstract]   [Full Text] [Related]  

  • 9. Rasagiline. Parkinson's disease: a simple me-too.
    Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17167927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rasagiline induced hypersexuality in Parkinson's disease.
    Reyes D; Kurako K; Galvez-Jimenez N
    J Clin Neurosci; 2014 Mar; 21(3):507-8. PubMed ID: 24055209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinergic-dopaminergic imbalance in Pisa syndrome.
    Villarejo A; Camacho A; García-Ramos R; Moreno T; Penas M; Juntas R; Ruiz J
    Clin Neuropharmacol; 2003; 26(3):119-21. PubMed ID: 12782913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of rasagiline in early Parkinson's disease.
    Lew MF; Hauser RA; Hurtig HI; Ondo WG; Wojcieszek J; Goren T; Fitzer-Attas CJ
    Int J Neurosci; 2010 Jun; 120(6):404-8. PubMed ID: 20504210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: A case report.
    Harada K
    Mov Disord; 2006 Dec; 21(12):2264; author reply 2264-5. PubMed ID: 17078069
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypersexuality induced by rasagiline in monotherapy in Parkinson's disease.
    Simonet C; Fernández B; Cerdán DM; Duarte J
    Neurol Sci; 2016 Nov; 37(11):1889-1890. PubMed ID: 27401808
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drug treatment for Parkinson's disease.
    FDA Consum; 2006; 40(4):7. PubMed ID: 17245831
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
    Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline. Teva Pharmaceutical.
    Kupsch A
    Curr Opin Investig Drugs; 2002 May; 3(5):794-7. PubMed ID: 12090555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.